Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial‐to‐mesenchymal transition
Paul Roepman(Leiden University Medical Center), Iris Simón(Leiden University Medical Center), Ulrich Nitsche(TUM Klinikum), Christine M. Chresta(AstraZeneca (United Kingdom)), Lodewyk F.A. Wessels(The Netherlands Cancer Institute), Mireille H.J. Snel(Agendia (Netherlands)), René Bernards(The Netherlands Cancer Institute), Ramón Salazar(Institut Català d'Oncologia), Gabriel Capellá(Institut Català d'Oncologia), Vı́ctor Moreno(Ajuntament de L’Hospitalet), Andreas Schlicker(Bayer (Germany)), Robert Rosenberg(Kantonsspital Baselland), Teresa Macarulla(Vall d'Hebron Hospital Universitari), George M. Orphanides(Howard Hughes Medical Institute), Ian J. Majewski(The University of Melbourne), Sun Tian(Agendia (Netherlands)), Josep Tabernero(Deaconess Hospital)
Cited by 350
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective
|JNCI Journal of the National Cancer Institute|1995|3.4k